P888: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY

por Askeland, F. B., Haukås, E., Slørdahl, T. S., Schjøll, D., Lysen, A., Hermansen, E., Schjesvold, F.
Publicado 2022

P950: COMBINED PROTEASOME AND AUTOPHAGY INHIBITION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA – A PHASE I TRIAL OF HYDROXYCHLOROQUINE, CARFILZOMIB AND DEXAMETHASONE

por Slørdahl, T. S., Askeland, F. B., Hanssen, M. S. S., Sundt-Hansen, S. M., Vethe, N. T., Hjorth-Hansen, H., Fenstad, M. H., Waage, A., Hjertner, Ø., Schjesvold, F., Sundan, A.
Publicado 2022

P889: WILL OUTCOME IMPROVE BY TREATING MULTIPLE MYELOMA PATIENTS AT MRD RELAPSE? THE REMNANT STUDY (RELAPSE FROM MRD NEGATIVITY AS INDICATION FOR TREATMENT)

por Askeland, F. B., Rasmussen, A.-M., Lysen, A., Haukås, E., Eilertsen, A., Moksnes, M., Tsykunova, G., Vik, A., Eiken, B. D., Sørbø, J. H., Rolke, J., Sand, K. O., Hallstensen, R. F., Myrseth, L., Slørdahl, T. S., Schjesvold, F.
Publicado 2022